[김창수의 e뉴스 브리핑] Yuhan Corporation to invest 10 billion won in April Bio… 2nd major shareholder registration, etc.

[FETV=김창수 기자] Yuhan Corporation announced that it was listed as the second largest shareholder by investing an additional 10 billion won in April Bio, which has the Serum Albumin Fragment Associated (SAFA) technology, and adding the existing stake. Daewoong Pharmaceutical announced on the 22nd that it has signed a joint R&D agreement with Oncocross, a company specializing in developing new drugs based on artificial intelligence, at its headquarters in Samseong-dong. On the 23rd, the Gasong Foundation of Bowon Pyo announced that it jointly selected’Asia Together’ with’Dentist Society Busan Gyeongnam Branch for a Healthy Society’ at the 10th Yoon Gwang-Yeol Dental Medical Service Award with the Korean Dental Association.

◆ Yuhan Corporation to invest 10 billion won in April Bio… Registered as the 2nd largest shareholder

Yuhan Corp. announced that it was listed as the second largest shareholder by investing an additional 10 billion won in April Bio, which has Serum Albumin Fragment Associated (SAFA) technology, adding its existing stake.

Established in 2013, April Bio is a new antibody drug company that develops global innovative new drugs in a variety of therapeutic areas using its proprietary human antibody library (HuDVFab) technology and SAFA, a sustained platform technology that can increase the half-life of antibody fragmentation.

April Bio is preparing for phase 1 clinical trial in the US this year, APB-A1, a preclinical inflammatory autoimmune disease treatment (targeted IL-18), APB-R3, male infertility treatment (FSH target) APB -R2, etc. are being developed.

◆ Daewoong Pharmaceutical to expand new drug indications in partnership with AI company

Daewoong Pharmaceutical will strengthen new drug development capabilities by signing an agreement with an artificial intelligence (AI) company.

Daewoong Pharmaceutical announced on the 22nd that it has signed a joint R&D agreement with Oncocross, a company specializing in artificial intelligence (AI)-based new drug development, at its headquarters in Samseong-dong.

Daewoong Pharmaceutical plans to expand the indications by incorporating Oncocross’s gene expression pattern-based AI platform’RAPTOR AI’ with the new drugs’Inabogliflozin’ and’DWN12088′ under development.

◆ Boe Pyo, Gasong Foundation-Korea Dental Association, selected as a winner of the 10th Yoon Kwang-Yeol Dental Medical Service Award

On the 23rd, the Gasong Foundation of Bowon Pyo announced that it jointly selected’Asia Together’ with’Dentist Society Busan Gyeongnam Branch for a Healthy Society’ at the 10th Yoon Gwang-Yeol Dental Medical Service Award with the Korean Dental Association.

The two organizations were honored with this award in recognition of their long-term dedication to improving the accessibility of dental care for marginalized neighbors. The awards ceremony is scheduled to be held on April 24 at the 70th General Assembly of the Korean Dental Association.

◆ Onyu Pharm launches premium lactobacillus’Prerobiotics 5.0′

Onyu Pharm has released the premium health functional food’Prerobiotics 5.0′.

‘Prerobiotics 5.0’ is a premium lactic acid bacteria product created by designing the ingredients directly by CEO Jeong Doo-sun, Onyu Pharm.

12 types of lactobacillus including breast-derived bacteria such as 8 lactobacillus, 3 Bifidobacterium, and 1 Streptococcus are blended.

It contains purezyme WS containing five digestive enzymes as an auxiliary ingredient, and fructooligosaccharide, which helps proliferate beneficial bacteria, is also added.

◆ Helix Miss, CEO Seung-shin Yoo, resigned as executive director

Helix Miss, CEO Yoo Seung-shin, resigns from the position of CEO and withdraws from the executive director. CEO Seung-shin Yoo made this decision to strengthen the company’s professionalism and independence and to reinforce the professional management system. Accordingly, CEO Yoo will withdraw from management and concentrate on clinical and research as Chief Technology Officer (CTO).

Representative Yoo Seung-shin, who is resigning from the position of CEO, is a Ph.D. in the Department of Microbiology at Seoul National University and is an employee of Helix Miss 1. From 2020, he took over as CEO of Helix Miss jointly with CEO Kim Sun-young.